Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake dataAug 6Quarterly updateNuvation Bio Inc.safusidenib
Nuvation Bio registers two new trials for IDH1-mutant glioma drug safusidenibJul 17Weekly roundup, 2 itemsNuvation Bio Inc.safusidenib
Sign inSign in